With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
655225-01-7, The compound obtained in Example 102-1 (45 mg, 0.27 mmol) in DMF (1 ml) solution of, tertiary butyl 4- (2-bromoethyl) piperazine-1-carboxylate (88 mg, 0.30 mmol) , it was added cesium carbonate (107 mg, 0.33 mmol). And stirred overnight at 70 , was solidified after the completion of the reaction was concentrated under reduced pressure to dryness. The residue was purified by silica gel column chromatography (chloroform / methanol) to give the title compound (95 mg, 92percent).
As the paragraph descriping shows that 655225-01-7 is playing an increasingly important role.
Reference£º
Patent; Yakult Honsha Co., Ltd.; University of Occupational and Environmental Health; Ono, Masahiro; Kobayashi, Tsuneyuki; Yamazaki, Ryuta; Haibara, Hirotake; Nishiyama, Yukiko; Hokkyo, Atsuko; Nishiyama, Hiroyuki; Kurita, Akinobu; Matsuzaki, Ken; Kono, Kimitoshi; Izumi, Hiroto; (215 pag.)JP2016/124812; (2016); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics